doi: 10.6004/jnccn.2020.0002.
NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020
Affiliations
- PMID: 31910384
- DOI: 10.6004/jnccn.2020.0002
Item in Clipboard
NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020
J Natl Compr Canc Netw.
2020 Jan.
Abstract
Management of febrile neutropenia (FN) is an integral part of supportive care for patients undergoing cancer treatment. The NCCN Guidelines for Hematopoietic Growth Factors provide suggestions for appropriate evaluation, risk determination, prophylaxis, and management of FN. These NCCN Guidelines are intended to guide clinicians in the appropriate use of growth factors for select patients undergoing treatment of nonmyeloid malignancies. These NCCN Guidelines Insights highlight important updates to the NCCN Guidelines regarding the incorporation of newly FDA-approved granulocyte-colony stimulating factor biosimilars for the prevention and treatment of FN.
Similar articles
-
Clinical Outcomes of Treatment with Filgrastim Versus a Filgrastim Biosimilar and Febrile Neutropenia-Associated Costs Among Patients with Nonmyeloid Cancer Undergoing Chemotherapy.J Manag Care Spec Pharm. 2018 Oct;24(10):976-984. doi: 10.18553/jmcp.2018.17447. Epub 2018 Apr 24. J Manag Care Spec Pharm. 2018. PMID: 29687743 Free PMC article.
-
NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022.J Natl Compr Canc Netw. 2022 May;20(5):436-442. doi: 10.6004/jnccn.2022.0026. J Natl Compr Canc Netw. 2022. PMID: 35545171
-
Pegfilgrastim-Apgf (Nyvepria): Biosimilar USFDA Approval for the Treatment of Chemotherapy-induced Febrile Neutropenia and Current Updates on Clinical Trials.Curr Drug Targets. 2022;23(9):924-932. doi: 10.2174/1389450123666220408101152. Curr Drug Targets. 2022. PMID: 35400340 Review.
-
RGB-02 (biosimilar pegfilgrastim) in the treatment of chemotherapy-induced neutropenia.Future Oncol. 2019 Jun;15(18):2083-2092. doi: 10.2217/fon-2018-0891. Epub 2019 Jun 18. Future Oncol. 2019. PMID: 31210542 Review.
-
Biosimilar filgrastim treatment patterns and prevention of febrile neutropenia: a prospective multicentre study in France in patients with solid tumours (the ZOHé study).BMC Cancer. 2018 Nov 16;18(1):1127. doi: 10.1186/s12885-018-4986-1. BMC Cancer. 2018. PMID: 30445935 Free PMC article.
Cited by
-
A prospective cohort study to evaluate the incidence of febrile neutropenia in patients receiving pegfilgrastim on-body injector versus other options for prophylaxis of febrile neutropenia: breast cancer subgroup analysis.Support Care Cancer. 2022 Jul;30(7):6135-6144. doi: 10.1007/s00520-022-07025-2. Epub 2022 Apr 14. Support Care Cancer. 2022. PMID: 35426046 Free PMC article.
-
Chinese expert consensus on the application of pegylated recombinant human granulocyte colony-stimulating factor during concurrent chemoradiotherapy (2023 edition).Precis Radiat Oncol. 2023 Sep 4;7(3):150-159. doi: 10.1002/pro6.1201. eCollection 2023 Sep. Precis Radiat Oncol. 2023. PMID: 40337203 Free PMC article.
-
Supportive therapies in the prevention of chemotherapy-induced febrile neutropenia and appropriate use of granulocyte colony-stimulating factors: a Delphi consensus statement.Support Care Cancer. 2022 Dec;30(12):9877-9888. doi: 10.1007/s00520-022-07430-7. Epub 2022 Nov 5. Support Care Cancer. 2022. PMID: 36334157 Free PMC article.
-
Predictive Role of Pre-Operative Anemia in Early Recurrence of Endometrial Cancer: A Single-Center Study in Romania.J Clin Med. 2024 Jan 30;13(3):794. doi: 10.3390/jcm13030794. J Clin Med. 2024. PMID: 38337488 Free PMC article.
-
Clinical Characteristics and Risk Factors of COVID-19 in 60 Adult Cancer Patients.Clin Med Insights Oncol. 2022 Jan 28;16:11795549221074168. doi: 10.1177/11795549221074168. eCollection 2022. Clin Med Insights Oncol. 2022. PMID: 35110966 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
